ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.771,79
-1,73%
S&P 500
5.344,87
-0,15%
US Dollar vs BRL
5,3219
1,20%
Bitcoin
69.268,01
-2,11%
Brent Oil
79,325
-0,69%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Point Therapeutics (MM) (POTP)

  7. Point Therapeutics (MM) (POTP) Notícias

POTP

Point Therapeutics (MM) (POTP)

Point Therapeutics (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:POTP
DataHoraFonteTítuloCódigoCompanhia
12/02/200819:15PR Newswire (US)DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of MergerNASDAQ:POTPPoint Therapeutics (MM)
12/02/200818:02Edgar (US Regulatory)Point Therapeutics Inc - Amended Statement of Ownership (SC 13G/A)NASDAQ:POTPPoint Therapeutics (MM)
11/02/200817:30Edgar (US Regulatory)Point Therapeutics Inc - Current report filing (8-K)NASDAQ:POTPPoint Therapeutics (MM)
11/02/200812:00Business WireUpdate on Point Therapeutics Merger with DARA BioSciencesNASDAQ:POTPPoint Therapeutics (MM)
08/02/200813:23Edgar (US Regulatory)Point Therapeutics Inc-Filing of certain prospectuses & communications for business combination transactions (425)NASDAQ:POTPPoint Therapeutics (MM)
04/02/200810:30PR Newswire (US)DARA BioSciences to Present at the ROTH Growth Stock ConferenceNASDAQ:POTPPoint Therapeutics (MM)
29/01/200819:30Business WirePoint Therapeutics Adjourns Meeting of Stockholders to February 12, 2008; DARA BioSciences Stockholders Approve Merger with PoinNASDAQ:POTPPoint Therapeutics (MM)
10/01/200811:00Business WirePoint Therapeutics Receives Additional Notice of Non-Compliance from NASDAQNASDAQ:POTPPoint Therapeutics (MM)
27/12/200711:30Business WirePoint Therapeutics Announces Form S-4 Registration Statement Declared Effective by SEC; Special Meeting of Stockholders Set forNASDAQ:POTPPoint Therapeutics (MM)
17/12/200720:12Edgar (US Regulatory)Point Therapeutics Inc - Registration Statement for securities to be issued in business combination transactions (S-4/A)NASDAQ:POTPPoint Therapeutics (MM)
17/12/200711:30Business WireNASDAQ Panel Grants Request of Point Therapeutics for Continued Listing on NASDAQ Capital MarketNASDAQ:POTPPoint Therapeutics (MM)
26/11/200710:13Edgar (US Regulatory)Point Therapeutics Inc - Securities Registration: Business Combination (S-4)NASDAQ:POTPPoint Therapeutics (MM)
09/11/200712:38Edgar (US Regulatory)Point Therapeutics Inc - Quarterly Report (10-Q)NASDAQ:POTPPoint Therapeutics (MM)
25/10/200709:00PR Newswire (US)DARA BioSciences, Inc. Announces New Board ChairmanNASDAQ:POTPPoint Therapeutics (MM)
17/10/200709:00PR Newswire (US)DARA BioSciences and Bayer Pharmaceuticals Corporation Sign Exclusive License AgreementNASDAQ:POTPPoint Therapeutics (MM)
09/08/200717:01Business WirePoint Therapeutics Reports Second Quarter 2007 Financial ResultsNASDAQ:POTPPoint Therapeutics (MM)
27/07/200708:30Business WirePoint Therapeutics Announces Further Management ReductionsNASDAQ:POTPPoint Therapeutics (MM)
12/07/200709:30Business WirePoint Therapeutics UpdateNASDAQ:POTPPoint Therapeutics (MM)
31/05/200709:00Business WirePoint Therapeutics Reduces Costs by Cutting Work ForceNASDAQ:POTPPoint Therapeutics (MM)
21/05/200709:00Business WireTalabostat Clinical Program Put on Clinical Hold by FDANASDAQ:POTPPoint Therapeutics (MM)
15/05/200711:02Business WireCORRECTING and REPLACING Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta StuNASDAQ:POTPPoint Therapeutics (MM)
15/05/200709:01Business WirePoint Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta StudyNASDAQ:POTPPoint Therapeutics (MM)
10/05/200709:00Business WirePoint Therapeutics Reports First Quarter 2007 Financial ResultsNASDAQ:POTPPoint Therapeutics (MM)
13/04/200709:00Business WirePoint Therapeutics Announces Preclinical Data Presentations at Upcoming American Association of Cancer Research Annual MeetingNASDAQ:POTPPoint Therapeutics (MM)
26/03/200709:24Business WirePoint Therapeutics Announces Management Change and Additional Information In Compliance With NASDAQ RulesNASDAQ:POTPPoint Therapeutics (MM)
16/03/200714:16Business WirePoint Therapeutics Reports Fourth Quarter and Year-End 2006 Financial ResultsNASDAQ:POTPPoint Therapeutics (MM)
13/03/200709:30Business WirePoint Therapeutics Receives Letter from Nasdaq Citing Non-Compliance with Minimum Bid Price RulesNASDAQ:POTPPoint Therapeutics (MM)
01/03/200709:25Business WirePoint Therapeutics Provides Clinical UpdateNASDAQ:POTPPoint Therapeutics (MM)
24/01/200711:12Business WirePoint Therapeutics Announces Resignation of William Whelan from Board of DirectorsNASDAQ:POTPPoint Therapeutics (MM)
12/01/200710:44Business WirePoint Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer StudyNASDAQ:POTPPoint Therapeutics (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:POTP

Seu Histórico Recente

AMEX
WEAT
Teucrium Wheat
COIN
AIIUSD
Multiverse
TSX
GMIN
G Mining Ventures
LSE
VM90
Barclays 26
LSE
ZU38
Sg Issuer 33
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados